Health Care·Pharmaceuticals·$789.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.98 | N/A | +2.19% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.98 | N/A | +2.19% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of cautious optimism regarding their financial performance. They emphasized their commitment to innovation and growth.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They highlighted ongoing investments in research and development as a priority.
Eli Lilly's earnings report shows that the company was able to beat expectations on EPS, which is a positive sign for investors. However, the lack of revenue data and guidance may leave some investors uncertain about future performance. The stock reaction was muted, indicating that investors are awaiting further clarity on revenue and growth prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CANADIAN NATL RY CO
Apr 24, 2017